LENZ LENZ Therapeutics Inc.

$LENZ I was having a chat with Gemini regarding the iPhone 18 Pro vs Pro Max decision I’m making. I mentioned my presbyopia as a reason for wanting the 18 Pro Max and the chat bot responded by suggesting I try VIZZ.

$LENZ My earlier warning still stands: hands off while FMR and the other kids are throwing with sand toys. The relevant question for retail is not whether $3.70 looks cheap. It is: when does the expected loss profile of the 10.63M remaining shorts become asymmetric? That requires: 1. Q3 validates the launch through product revenue, refills and a strong September exit rate. 2. LENZ shows a credible path toward roughly 1% US market reach (= BofA's ~$370M rating after Q2). 3. The stock reclaims $5.55 (holds $6 on real volume). 4. Short interest remains crowded as supply stays tight. At that point, every additional fundamental confirmation can force covering into a market with little natural supply. That is the potential retail entry window — not trying to catch the stock during institutional distribution. If LENZ makes that path credible, the shorts’ remaining reward is limited while their potential loss becomes open-ended. Until then: no hero trades. Watch the evidence.

$LENZ 2026-10-06 a nice hammer with good vol. on 1m,3m,6m frames. love it. looking great on weekly ✅️

$LENZ LOL this was an absolute massacre. And this is why smallcaps are scams. The fact that management hasn’t bought at current levels means they will likely take it private and screw all shareholders. Afterall the large short positions here are probably done by themselves regardless, so I am not that surprised.

$LENZ I’ve tried to warn everyone about this stock since $30. There’s no market for it. The side effects are horrible. They burn through cash like nobody’s business. Will be bankrupt soon. Those who’ve listened have been making money shorting this piece of shit.

$LENZ rumors swirling about ditching optometrists/ophthalmologists and going to tele-health system. What a mistake if true. The only reason they’d do this is because health care providers aren’t recommending this product due to side effect profile and adverse events. We all knew the product was bad, but this decision may take the cake.

$LENZ Every day we see a new 52 week low. Should we now assume this is not just from the poor execution? Who thinks a lot of their balance sheets short term investments were in US treasuries and have gotten stomped with the yield surge? Day after day of beatings here